Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akums Drugs and PharmaceuticalsNSE:AKUMS +0.75%39 Pretax Margin % is 10.47% as of Mar. 2026, which is 95% above its 10-year median of 5.36. GuruFocus rates NSE:AKUMS with a GF Score™ of 39/100. The stock has 7 warning signs investors should review. Among 961 Drug Manufacturers companies, Akums Drugs and Pharmaceuticals ranks better than 54.63% on this metric.
The historical rank and industry rank for Akums Drugs and Pharmaceuticals's Pretax Margin % or its related term are showing as below:
NSE:AKUMS'
s Pretax Margin % Range Over the Past 10 Years
Min: -5.3 Med: 5.36 Max: 8.99
Current: 8.77
NSE:AKUMS's Pretax Margin % is ranked better than 54.63% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs NSE:AKUMS: 8.77
Akums Drugs and Pharmaceuticals (NSE:AKUMS) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Akums Drugs and Pharmaceuticals Pretax Margin % Related Terms
Akums Drugs and Pharmaceuticals Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akums Drugs and Pharmaceuticals Pretax Margin % Chart
NSE:AKUMS vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akums Drugs and Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akums Drugs and Pharmaceuticals Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akums Drugs and Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Akums Drugs and Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a Pretax Margin % of 10.47% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Akums Drugs and Pharmaceuticals and its competitors. This is 95% above median its historical median of 5.36. According to the industry distribution chart, Akums Drugs and Pharmaceuticals ranks #436 out of 961 companies in the Drug Manufacturers industry, placing it in the top 45.4%.
Is Akums Drugs and Pharmaceuticals' Pretax Margin % too high?
Akums Drugs and Pharmaceuticals' current Pretax Margin % of 10.47% is 95% above median its 10-year median of 5.36. The Drug Manufacturers industry median Pretax Margin % is 7.28. Akums Drugs and Pharmaceuticals' value of 10.47% is 43.8% above this industry median. Based on the distribution chart, Akums Drugs and Pharmaceuticals ranks #436 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Akums Drugs and Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Akums Drugs and Pharmaceuticals' Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Akums Drugs and Pharmaceuticals ranks #436 out of 961 companies for Pretax Margin %. This puts Akums Drugs and Pharmaceuticals in the upper half of its industry. The industry median Pretax Margin % is 7.28. Akums Drugs and Pharmaceuticals' value of 10.47% is 43.8% above this benchmark. While the company's 10-year median is 5.36 vs. the industry median of 7.28, Akums Drugs and Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akums Drugs and Pharmaceuticals's current Pretax Margin % of 10.47% is 43.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Akums Drugs and Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akums Drugs and Pharmaceuticals's current Pretax Margin % is 10.47%, which is 95% above median its own 10-year median of 5.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akums Drugs and Pharmaceuticals stock overvalued right now?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a current Pretax Margin % of 10.47%. The current Pretax Margin % is 10.47%, which is 95% above median its 10-year median of 5.36 and 43.8% above the Drug Manufacturers industry median of 7.28. Akums Drugs and Pharmaceuticals' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Akums Drugs and Pharmaceuticals (NSE:AKUMS), the current Pretax Margin % is 10.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akums Drugs and Pharmaceuticals Business Description
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates in five segments: Contract Development and Manufacturing Operations, Active Pharmaceutical Ingredient (API), Domestic Branded formulations, International Branded Formulations, and Trade generics. Key revenue is generated from Contract Development and Manufacturing Operations.
39GF Score
Get the complete analysis for NSE:AKUMS
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AKUMS has been successfully added to your 
